(6)
The amounts shown and the following information were provided by Sofinnova Venture Partners X, L.P. pursuant to a Schedule 13D filed with the SEC on October 2, 2018 as amended and restated by amendment No. 1 thereto filed with the SEC on February 15, 2022. The voting and investment control of the shares owned by Sofinnova Venture Partners X, L.P. are held by Maha Katabi, Ph.D., CFA and Dr. James I. Healy, the managing members of Sofinnova Management X-A, L.L.C., the General Partner of Sofinnova Management X, L.P., the General Partner of Sofinnova Venture Partners X, L.P.
(7)
Includes (i) 565,032 shares of common stock owned by GAD Enterprises LLC, of which Mr. Gad is the sole member and manager and as such Mr. Gad has sole voting and dispositive power with respect to such shares, (ii) 50,000 shares owned by Mr. Gad outright; (iii) 60,000 shares of common stock owned by Mr. Gad’s children who are deemed to share the same household, and (iv) 764,001 shares of common stock underlying securities that are exercisable as of April 13, 2023 or will become exercisable within 60 days after such date.
(8)
Includes (i) 622,928 shares of common stock owned directly by Dr. Møller and (ii) 1,507,879 shares of common stock underlying securities that are exercisable as of April 13, 2023 or will become exercisable within 60 days after such date.
(9)
Includes (i) 181,077 shares of common stock owned directly by Mr. Kruse and (ii) 854,982 shares of common stock underlying securities that are exercisable as of April 13, 2023 or will become exercisable within 60 days after such date.
(10)
Includes 33,500 shares of common stock underlying securities that are exercisable by Ms. Smith as of April 13, 2023, or will become exercisable within 60 days after such date.
(11)
Includes (i) 4,178,465 shares of common stock owned by WG Biotech ApS in which Mr. Wedell-Wedellsborg is the majority owner and as such has sole voting and dispositive power with respect to such shares and (ii) 129,333 shares of common stock underlying securities that are exercisable as of April 13, 2023, or will become exercisable within 60 days after such date.
(12)
Includes 60,444 shares of common stock underlying securities that are exercisable by Ms. Hamill as of April 13, 2023, or will become exercisable within 60 days after such date.
(13)
Includes 93,333 shares of common stock underlying securities that are exercisable by Dr. Ber as of April 13, 2023, or will become exercisable within 60 days after such date.
(14)
Includes (i) 2,194,278 shares of common stock owned by Sofinnova Venture Partners X, L.P. Dr. Healy is a managing member of Sofinnova Management X-A, L.L.C., the General Partner of Sofinnova Venture Partners X, L.P., and as such has voting and dispositive power over such shares with Maha Katabi, Ph.D., CFA, the other managing member of Sofinnova Management X, L.L.C.; (ii) 25,778 shares owned outright by Dr. Healy; and (iii) 67,555 shares of common stock underlying securities that are owned outright by Dr. Healy and which are exercisable as of April 13, 2023 or will become exercisable within 60 days after such date.
(15)
Includes 92,444 shares of common stock underlying options that are exercisable by Dr. Tyagi as of April 13, 2023, or will become exercisable within 60 days after such date.
(16)
Includes 85,333 shares of common stock underlying securities that are exercisable by Mr. Gill as of April 13, 2023, or will become exercisable within 60 days after such date.
(17)
Includes 2,684,178 shares of common stock underlying securities that are exercisable as of April 13, 2023, or will become exercisable within 60 days after such date.